Aliases & Classifications for Prostatic Hypertrophy

MalaCards integrated aliases for Prostatic Hypertrophy:

Name: Prostatic Hypertrophy 12 15 73
Benign Prostatic Hypertrophy 73
Prostatic Hyperplasia 73

Classifications:



External Ids:

Disease Ontology 12 DOID:11132

Summaries for Prostatic Hypertrophy

MalaCards based summary : Prostatic Hypertrophy, also known as benign prostatic hypertrophy, is related to leiomyoma and prostatic hyperplasia, benign, and has symptoms including prostatism An important gene associated with Prostatic Hypertrophy is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are Gastric cancer and Pathways in cancer. The drugs Alfuzosin and Tamsulosin have been mentioned in the context of this disorder. Affiliated tissues include prostate, liver and testes, and related phenotypes are behavior/neurological and cardiovascular system

Related Diseases for Prostatic Hypertrophy

Diseases related to Prostatic Hypertrophy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 150)
# Related Disease Score Top Affiliating Genes
1 leiomyoma 29.9 CYP19A1 ESR1 PGR
2 prostatic hyperplasia, benign 29.5 ADRA1A AR CYP19A1 KLK3
3 prostatitis 11.0
4 prostatic adenoma 10.8 AR KLK3
5 nodular prostate 10.8 AR KLK3
6 prostatic acinar adenocarcinoma 10.7 AR KLK3
7 postmenopausal atrophic vaginitis 10.7 AR ESR1
8 androgen insensitivity, partial 10.7 AR CYP19A1
9 vulvar syringoma 10.7 ESR1 PGR
10 lung leiomyoma 10.7 ESR1 PGR
11 transsexualism 10.7 AR CYP19A1
12 vestibular gland benign neoplasm 10.7 ESR1 PGR
13 bartholin's gland adenoma 10.7 ESR1 PGR
14 glassy cell carcinoma of the cervix 10.7 ESR1 PGR
15 vulvar benign neoplasm 10.7 ESR1 PGR
16 trigonitis 10.7 ESR1 PGR
17 vulvar leiomyoma 10.7 ESR1 PGR
18 predominantly cortical thymoma 10.7 ESR1 PGR
19 alopecia, androgenetic, 1 10.7 AR CYP19A1
20 breast medullary carcinoma 10.7 ESR1 PGR
21 breast scirrhous carcinoma 10.7 ESR1 PGR
22 progesterone resistance 10.7 ESR1 PGR
23 cribriform carcinoma 10.7 ESR1 PGR
24 gastric signet ring cell adenocarcinoma 10.6 ESR1 PGR
25 endometrial disease 10.6 CYP19A1 ESR1
26 endometrial mucinous adenocarcinoma 10.6 ESR1 PGR
27 adenoid basal cell carcinoma 10.6 ESR1 PGR
28 bartholin's gland benign neoplasm 10.6 ESR1 PGR
29 deep angioma 10.6 ESR1 PGR
30 synchronous bilateral breast carcinoma 10.6 ESR1 PGR
31 aromatase deficiency 10.6 CYP19A1 ESR1
32 benign metastasizing leiomyoma 10.6 CYP19A1 PGR
33 cervical carcinosarcoma 10.6 ESR1 PGR
34 withdrawal disorder 10.6 AR KLK3
35 intramuscular hemangioma 10.6 ESR1 PGR
36 glycogen-rich clear cell breast carcinoma 10.6 ESR1 PGR
37 retinitis pigmentosa 47 10.6 ESR1 PGR
38 uterine corpus cancer 10.6 ESR1 PGR
39 vaginitis 10.6 AR ESR1
40 adenomyosis 10.6 ESR1 PGR
41 retinitis pigmentosa 20 10.6 ESR1 PGR
42 luminal breast carcinoma 10.6 ESR1 PGR
43 corneal abscess 10.6 AR PGR
44 adenosarcoma 10.6 ESR1 PGR
45 cervical clear cell adenocarcinoma 10.6 ESR1 PGR
46 breast benign neoplasm 10.6 ESR1 PGR
47 thoracic benign neoplasm 10.6 ESR1 PGR
48 endometrial stromal nodule 10.6 CYP19A1 PGR
49 inflammatory breast carcinoma 10.5 ESR1 PGR
50 papillary hidradenoma 10.5 AR PGR

Comorbidity relations with Prostatic Hypertrophy via Phenotypic Disease Network (PDN): (show top 50) (show all 52)


Acute Cystitis Acute Kidney Failure
Anthracosis Asbestosis
Balanoposthitis Bladder Cancer
Bladder Disease Bladder Neck Obstruction
Chronic Kidney Failure Chronic Myocardial Ischemia
Cystitis Cystitis Cystica
Epididymo-Orchitis First-Degree Atrioventricular Block
Generalized Atherosclerosis Gout
Hydronephrosis Infected Hydrocele
Interstitial Cystitis Ischemic Heart Disease
Kidney Disease Left Bundle Branch Hemiblock
Lipoma of Spermatic Cord Low Compliance Bladder
Nephrolithiasis, X-Linked Recessive, with Renal Failure Neurogenic Bladder
Parkinson Disease, Late-Onset Pelvic Varices
Penile Disease Peyronie's Disease
Pinta Disease Pneumoconiosis
Postinflammatory Pulmonary Fibrosis Prostate Calculus
Prostate Cancer Prostate Carcinoma in Situ
Prostate Disease Prostatitis
Prostatocystitis Renal Pelvis Carcinoma
Right Bundle Branch Block Silicosis
Spermatocele Ureter, Cancer of
Ureterolithiasis Urethral Benign Neoplasm
Urethral Calculus Urethral Stricture
Urethritis Urinary Tract Obstruction

Graphical network of the top 20 diseases related to Prostatic Hypertrophy:



Diseases related to Prostatic Hypertrophy

Symptoms & Phenotypes for Prostatic Hypertrophy

UMLS symptoms related to Prostatic Hypertrophy:


prostatism

MGI Mouse Phenotypes related to Prostatic Hypertrophy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.01 FGF8 LGALS8 CD36 PGR CYP19A1 ADRA1A
2 cardiovascular system MP:0005385 9.91 AR FGF8 CD36 PGR CYP19A1 ADRA1A
3 digestive/alimentary MP:0005381 9.8 CD36 CYP19A1 EGF ESR1 AR FGF8
4 endocrine/exocrine gland MP:0005379 9.8 FGF8 CD36 PGR CYP19A1 EGF ESR1
5 immune system MP:0005387 9.76 FGF8 LGALS8 CD36 PGR CYP19A1 EGF
6 muscle MP:0005369 9.5 CD36 PGR CYP19A1 ESR1 ADRA1A AR
7 renal/urinary system MP:0005367 9.1 CD36 CYP19A1 ESR1 ADRA1A AR FGF8

Drugs & Therapeutics for Prostatic Hypertrophy

Drugs for Prostatic Hypertrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 100)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alfuzosin Approved, Investigational Phase 4,Phase 3,Not Applicable 81403-80-7 2092
2
Tamsulosin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 106133-20-4 129211
3 Mirabegron Approved Phase 4 223673-61-8 9865528
4
Silodosin Approved Phase 4 160970-54-7
5
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
6
Mivacurium Approved Phase 4 106791-40-6, 133814-19-4 5281042
7
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
8
Dihydrotachysterol Approved Phase 4 67-96-9 5281010 5311071
9
Dutasteride Approved, Investigational Phase 4,Phase 3,Not Applicable 164656-23-9 152945 6918296
10
Methyltestosterone Approved Phase 4,Phase 2 58-18-4 6010
11
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2 58-22-0 6013
12
Testosterone enanthate Approved Phase 4,Phase 2 315-37-7 9416
13
Testosterone undecanoate Approved, Investigational Phase 4,Phase 2 5949-44-0
14
Dihydrotestosterone Illicit, Investigational Phase 4 521-18-6 10635
15 Adrenergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
16 Adrenergic alpha-1 Receptor Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
17 Adrenergic alpha-Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
18 Adrenergic Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
19 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
20 Mitogens Phase 4,Not Applicable
21 Adrenergic Agonists Phase 4,Not Applicable
22 Adrenergic beta-3 Receptor Agonists Phase 4
23 Adrenergic beta-Agonists Phase 4
24 Anesthetics Phase 4,Not Applicable
25 Cholinergic Agents Phase 4,Phase 3,Phase 2
26 Cholinergic Antagonists Phase 4,Phase 2,Phase 3
27 Neuromuscular Agents Phase 4,Phase 3
28 Neuromuscular Blocking Agents Phase 4
29 Neuromuscular Nondepolarizing Agents Phase 4
30 Peripheral Nervous System Agents Phase 4,Phase 3,Not Applicable
31 Muscarinic Antagonists Phase 4,Phase 2,Phase 3
32 Solifenacin succinate Phase 4 242478-38-2
33 5-alpha Reductase Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
34 Anabolic Agents Phase 4,Phase 2
35 Androgens Phase 4,Phase 3,Phase 2,Not Applicable
36 Antineoplastic Agents, Hormonal Phase 4,Phase 2
37 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
38 Hormones Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
39 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
40 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
41 Testosterone 17 beta-cypionate Phase 4,Phase 2
42
Cetrorelix Approved, Investigational Phase 3 120287-85-6 16129715 25074887
43
Acetylcholine Approved Phase 3 51-84-3 187
44
Doxazosin Approved Phase 3 74191-85-8 3157
45
Finasteride Approved Phase 3,Phase 1,Phase 2,Not Applicable 98319-26-7 57363
46 Antihypertensive Agents Phase 3,Not Applicable
47 Fertility Agents Phase 3
48 incobotulinumtoxinA Phase 3
49 Tolterodine tartrate Phase 2, Phase 3 124937-52-6
50
Tadalafil Approved, Investigational Phase 2,Phase 1 171596-29-5 110635

Interventional clinical trials:

(show top 50) (show all 80)
# Name Status NCT ID Phase Drugs
1 Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL®) in Patients With Benign Prostate Hypertrophy Completed NCT00542165 Phase 4 Alfuzosin
2 A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH) Completed NCT02656173 Phase 4 Mirabegron;Placebo
3 Safety and Efficacy of QD Versus BID Silodosin With Lower Urinary Tract Symptoms Suggestive of BPH Completed NCT01260129 Phase 4 Silodosin;Silodosin
4 Effect of Deep BLock on Intraoperative Surgical Conditions Completed NCT01631149 Phase 4 Surgical block (rocuronium; atracurium/mivacurium);Surgical block (rocuronium; atracurium/mivacurium)
5 Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia Completed NCT00771394 Phase 4 Tamsulosin hydrochloride;Solifenacin succinate
6 Efficacy Study for Use of Dutasteride (Avodart) With Testosterone Replacement Completed NCT00752869 Phase 4 dutasteride;placebo
7 Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer Completed NCT00375765 Phase 4 Dutasteride
8 Pilot Trial Of Urinary Nerve Growth Factor (NGF) As Biomarker for Male Lower Urinary Tract Symptoms Completed NCT01457573 Phase 4 Tamsulosin;Solifenacin
9 Preoperative Administration of Tamsulosin for Prevention of Post Operative Urinary Retention in Males Undergoing Elective Inguinal Hernia Repair Enrolling by invitation NCT02958878 Phase 4 Tamsulosin;Placebo Oral Capsule
10 Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH) Completed NCT00663858 Phase 3 Cetrorelix 78+78;Cetrorelix 78 + Placebo
11 The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate Completed NCT00427219 Phase 2, Phase 3 Ozarelix/Placebo;Placebo
12 Study to Assess the Efficacy of Medi-Tate TIND Device Completed NCT02145208 Phase 3
13 A-botulinic Toxin for Symptomatic Benign Prostate Hypertrophy Completed NCT01275521 Phase 3 BONT-A intra-prostatic injection;Optimized medical BPH treatment
14 Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH) Completed NCT00670306 Phase 3 Cetrorelix Pamoate
15 Medical Therapy of Prostatic Symptoms (MTOPS) Completed NCT00021814 Phase 3 Doxazosin;Finasteride
16 Clinical Trial in Males With BPH (Enlarged Prostate) Completed NCT00029822 Phase 3 Alfuzosin (SL770499)
17 "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk Completed NCT00056407 Phase 3 Dutasteride;Placebo
18 Combined Behavioral and Drug Treatment of Overactive Bladder in Men Completed NCT01175382 Phase 2, Phase 3 Tolterodine + tamsulosin
19 Predicting Responses to PTSD Treatment With Iris and Cardiovascular Tests Recruiting NCT03539614 Phase 3 Prazosin;Placebo
20 Cetrorelix Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH) Terminated NCT00449150 Phase 3 Cetrorelix 78 mg + 78 mg;Cetrorelix 78 mg + 52 mg;Placebo
21 H-36731: Finasteride in Management of Elevated Red Blood Cells Withdrawn NCT02548117 Phase 3 Finasteride
22 A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH). Unknown status NCT00044226 Phase 2 ML-04A
23 Vardenafil in Greenlight(TM) Laser Surgery of Benign Prostate Hypertrophy Completed NCT00461123 Phase 2 Vardenafil (Levitra, BAY38-9456);Placebo
24 Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT00386009 Phase 2 Tadalafil;Placebo
25 Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate) Completed NCT00037141 Phase 1, Phase 2 dehydrated alcohol
26 A Clinical Study to Determine Factors Affecting Absorption and Serum Levels of Lycopene After Supplementation Completed NCT00154843 Phase 2 Lycopene
27 Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy Completed NCT01227993 Phase 1, Phase 2 Finasteride
28 5-Alpha Reductase and Anabolic Effects of Testosterone Completed NCT00475501 Phase 2 Testosterone Enanthate;Finasteride;Testosterone Enanthate;Finasteride
29 Prostate Embolization for Massive Benign Prostatic Hypertrophy (BPH) Recruiting NCT02676544 Phase 1, Phase 2
30 Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy Recruiting NCT02961114 Phase 1, Phase 2
31 Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter Recruiting NCT03423979 Phase 2 Paclitaxel
32 Prostate Artery Embolization as a Treatment for Benign Prostatic Hyperplasia in Men With Prostates Larger Than 90 Grams Active, not recruiting NCT02396420 Phase 2
33 Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy Active, not recruiting NCT01446991 Phase 2 Degarelix;Degarelix
34 Dose Response Study of VA106483 in Males With Nocturia and Benign Prostatic Hypertrophy (BPH) Completed NCT01330927 Phase 1 VA106483
35 A Clinical Trial to Evaluate the Effects of Food on the Bioavailability of CKD-397 in Healthy Male Subjects Completed NCT02615782 Phase 1 CKD-397
36 Prostate Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia Recruiting NCT02592473 Phase 1
37 Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED) Unknown status NCT00256399 Not Applicable Alfuzosin 10 mg
38 Prognostic Value of the Urinary Nerve Growth Factor in the Patients With Benign Prostatic Hyperplasia Unknown status NCT01781117 Not Applicable
39 The Effect of Anterior Corneal Incisions on Intraoperative Floppy Iris Syndrome (IFIS) Incidence and Severity in Tamsulosin Treated Cataract Patients Unknown status NCT01070602 Not Applicable
40 The Effectiveness of 18F-fluorocholine Positron Emission Tomography (PET) in Detecting, Staging and Following-up Prostate Cancer Unknown status NCT01089881
41 Observational Study to Investigate the Effectiveness of Eprosartan on Pulse Pressure (Teveten_MS) Unknown status NCT02024100
42 Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan Completed NCT01323998 5ARI;AB
43 MRI and Magnetic Resonance Spectroscopy Imaging in Patients Receiving Dutasteride for Benign Prostatic Hypertrophy and Low-Risk Prostate Cancer Completed NCT00706966 Not Applicable dutasteride
44 Plasmakinetic Enucleation of the Prostate to Treat Benign Prostatic Hypertrophy Patients With Large Prostate Completed NCT01637701 Not Applicable
45 Assessing the Impact of the PVP With Greenlight Laser Using Prostatic MRI and Contrast-enhanced Ultrasound Completed NCT01732991 Not Applicable
46 The Effect of Spermatic Vein Embolization on Prostatic Hypertrophy Completed NCT00639899 Not Applicable
47 Prostate Cancer Antigen 3 (PCA-3) Gene Project Completed NCT01177436 Not Applicable
48 Dutasteride After Failure of Finasteride In the Management of Symptomatic Prostatic Enlargement/Hypertrophy (BPE/H) Completed NCT00382356 Not Applicable Dutasteride
49 Saline With Alcohol in TransUrethral Resection aNd Photoselective Vaporisation of the Prostate Completed NCT02429219 Not Applicable Saline Irrigation with Ethanol
50 The Effects of Intrathecal Dexmedetomidine on Spinal Anesthesia Using Diluted Low-Dose Bupivacaine for Transurethral Resection of Prostate in Elderly Completed NCT01342562 Not Applicable spinal anesthesia;spinal anesthesia

Search NIH Clinical Center for Prostatic Hypertrophy

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Prostatic Hypertrophy

Anatomical Context for Prostatic Hypertrophy

MalaCards organs/tissues related to Prostatic Hypertrophy:

41
Prostate, Liver, Testes, Heart, Breast, Kidney, Appendix

Publications for Prostatic Hypertrophy

Articles related to Prostatic Hypertrophy:

(show top 50) (show all 548)
# Title Authors Year
1
Emerging, newly-approved treatments for lower urinary tract symptoms secondary to benign prostatic hypertrophy. ( 29679999 )
2018
2
Investigational procedures in benign prostatic hypertrophy. ( 29528973 )
2018
3
Benign prostatic hypertrophy: PycnogenolAr supplementation improves prostate symptoms and residual bladder volume. ( 29947491 )
2018
4
Prostate Artery Embolization for Complete Urinary Outflow Obstruction Due to Benign Prostatic Hypertrophy. ( 27853823 )
2017
5
Investigating the link between benign prostatic hypertrophy, BMI and type 2 diabetes mellitus. ( 28433616 )
2017
6
Lower urinary tract symptoms/benign prostatic hypertrophy and vascular function: Role of the nitric oxide-phosphodiesterase type 5-cyclic guanosine 3',5'-monophosphate pathway. ( 28332240 )
2017
7
Case-Control Study of Intra-arterial Verapamil for Intraprostatic Anastomoses to Extraprostatic Arteries in Prostatic Artery Embolization for Benign Prostatic Hypertrophy. ( 28506701 )
2017
8
Minimally invasive surgical therapies for benign prostatic hypertrophy: The rise in minimally invasive surgical therapies. ( 28593165 )
2017
9
Ageratum conyzoides L. inhibits 5-alpha-reductase gene expression in human prostate cells and reduces symptoms of benign prostatic hypertrophy in otherwise healthy men in a double blind randomized placebo controlled clinical study. ( 29048765 )
2017
10
The androgen receptor plays different roles in macrophage-induced proliferation in prostate stromal cells between transitional and peripheral zones of benign prostatic hypertrophy. ( 28694768 )
2017
11
Can the UroLift prostatic implant device treat the symptoms of benign prostatic hypertrophy, avoid sexual dysfunction and reduce hospital TURP waiting times? A single centre, single surgeon experience and review of the literature. ( 28609136 )
2017
12
Donegal Going against the Flow: National Differences in Long-Term Urinary Catheterisation Rates in Men (> 65 Years) With Benign Prostatic Hypertrophy. ( 29372955 )
2017
13
Re: Stroke Associated with Alpha Blocker Therapy for Benign Prostatic Hypertrophy. ( 27321530 )
2016
14
Treatment of lower urinary tract symptoms in benign prostatic hypertrophy with I+-blockers. ( 27629686 )
2016
15
Inhibitory Activities of Phenolic Compounds Isolated from Adina rubella Leaves Against 5I+-Reductase Associated with Benign Prostatic Hypertrophy. ( 27399661 )
2016
16
Kidney transplant complications from undiagnosed benign prostatic hypertrophy. ( 25832848 )
2015
17
Varicocele: the origin of benign prostatic hypertrophy? Testosterone dosages in the periprostatic plexus. ( 26290288 )
2015
18
The Role of Minimally Invasive Surgical Techniques in the Management of Large-gland Benign Prostatic Hypertrophy. ( 26543428 )
2015
19
Supplementary management of benign prostatic hypertrophy with Prostaquil. An 8-week registry. ( 26492588 )
2015
20
Clinical Outcomes of Transurethral Enucleation with Bipolar for Benign Prostatic Hypertrophy. ( 26662662 )
2015
21
The Impact of Medical and Surgical Treatment for Benign Prostatic Hypertrophy on Erectile Function. ( 26438220 )
2015
22
Effects of I+-blocker therapy on active duty military and military retirees for benign prostatic hypertrophy on diabetic complications. ( 25735029 )
2015
23
Preparation, characterization and stability study of dutasteride loaded nanoemulsion for treatment of benign prostatic hypertrophy. ( 25587300 )
2014
24
Bipolar transurethral resection versus monopolar transurethral resection for benign prostatic hypertrophy: a systematic review and meta-analysis. ( 24754254 )
2014
25
Estrogen receptor beta agonist LY500307 fails to improve symptoms in men with enlarged prostate secondary to benign prostatic hypertrophy. ( 25348255 )
2014
26
Efficacy of Long-Term Daily Dosage of Alfuzosin 10 mg upon Sexual Function of Benign Prostatic Hypertrophy Patients: Two-Year Prospective Observational Study. ( 25606561 )
2014
27
Re: Editorial comment on constitutional, organopathic and combined homeopathic treatment of benign prostatic hypertrophy: a clinical trial: S. A. Kaplan J Urol 2013; 190: 1818-1819. ( 24892642 )
2014
28
Surgical therapy for benign prostatic hypertrophy/bladder outflow obstruction. ( 24744521 )
2014
29
Tadalafil and benign prostatic hypertrophy. Too risky. ( 24860894 )
2014
30
Bilateral ureteral obstruction revealing a benign prostatic hypertrophy: a case report and review of the literature. ( 24513237 )
2014
31
Re: a phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. ( 25629105 )
2014
32
Re: Constitutional, organopathic and combined homeopathic treatment of benign prostatic hypertrophy: a clinical trial. ( 24120797 )
2013
33
A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. ( 23642948 )
2013
34
Successful minimally-invasive management of a case of giant prostatic hypertrophy associated with recurrent nephrogenic adenoma of the prostate. ( 23565707 )
2013
35
Alpha-1 adrenergic antagonists in aircrew for the treatment of benign prostatic hypertrophy. ( 23305000 )
2013
36
Correlation of transrectal and transabodominal ultrasound measurement of transition zone volume with post-operative enucleated adenoma volume in benign prostatic hypertrophy. ( 24876907 )
2013
37
American Urological Association and European Association of Urology guidelines in the management of benign prostatic hypertrophy: revisited. ( 22123290 )
2012
38
Constitutional, organopathic and combined homeopathic treatment of benign prostatic hypertrophy: a clinical trial. ( 23089217 )
2012
39
The early days of prostatectomy for benign prostatic hypertrophy. ( 22132481 )
2011
40
Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study. ( 21171937 )
2011
41
Carvedilol for the treatment of benign prostatic hypertrophy in patients with heart failure? ( 21962427 )
2011
42
Sphaeranthus indicus attenuates testosterone induced prostatic hypertrophy in albino rats. ( 21503998 )
2011
43
[Sexual problems in patients with prostate cancer and those with benign prostatic hypertrophy]. ( 21542379 )
2011
44
Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy. ( 21221201 )
2010
45
Serenoa repens in benign prostatic hypertrophy: analysis of 2 Italian studies. ( 20944533 )
2010
46
Effect of Benincasa hispida fruits on testosterone-induced prostatic hypertrophy in albino rats. ( 24688153 )
2010
47
Increased frequency and nocturia in a middle aged male may not always be due to Benign Prostatic Hypertrophy (BPH): a case report. ( 19946479 )
2009
48
Acute colonic obstruction due to benign prostatic hypertrophy. ( 19405320 )
2009
49
[Oxidative stress in prostate hypertrophy and carcinogenesis]. ( 19644150 )
2009
50
Pharmacological management of benign prostatic hypertrophy with phosphodiesterase-5 inhibitors. ( 20017412 )
2009

Variations for Prostatic Hypertrophy

Expression for Prostatic Hypertrophy

Search GEO for disease gene expression data for Prostatic Hypertrophy.

Pathways for Prostatic Hypertrophy

GO Terms for Prostatic Hypertrophy

Biological processes related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.73 AR CD36 EGF FGF8
2 transcription initiation from RNA polymerase II promoter GO:0006367 9.72 AR ESR1 PGR
3 positive regulation of protein kinase B signaling GO:0051897 9.7 EGF ESR1 FGF8
4 positive regulation of MAPK cascade GO:0043410 9.69 ADRA1A AR CD36
5 positive regulation of cytosolic calcium ion concentration GO:0007204 9.67 ADRA1A CD36 ESR1
6 mammary gland development GO:0030879 9.58 CYP19A1 PGR
7 positive regulation of phosphorylation GO:0042327 9.57 AR EGF
8 sex differentiation GO:0007548 9.56 AR SRY
9 positive regulation of mitotic nuclear division GO:0045840 9.54 EGF FGF8
10 phosphatidylinositol phosphorylation GO:0046854 9.54 EGF ESR1 FGF8
11 androgen metabolic process GO:0008209 9.48 CYP19A1 ESR1
12 uterus development GO:0060065 9.46 CYP19A1 ESR1
13 steroid hormone mediated signaling pathway GO:0043401 9.43 AR ESR1 PGR
14 regulation of systemic arterial blood pressure GO:0003073 9.4 AR KLK3
15 prostate gland growth GO:0060736 9.32 AR CYP19A1
16 regulation of toll-like receptor signaling pathway GO:0034121 9.16 CD36 ESR1
17 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 8.96 AR PGR
18 mammary gland alveolus development GO:0060749 8.8 AR EGF ESR1

Molecular functions related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lipid binding GO:0008289 9.67 AR CD36 ESR1 PGR
2 ATPase binding GO:0051117 9.5 AR ESR1 PGR
3 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.43 EGF ESR1 FGF8
4 steroid hormone receptor activity GO:0003707 9.33 AR ESR1 PGR
5 nuclear receptor activity GO:0004879 9.13 AR ESR1 PGR
6 steroid binding GO:0005496 8.8 AR ESR1 PGR

Sources for Prostatic Hypertrophy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....